Profiles Of De Novo CD25-Positive Mature B-Cell Lymphomas
Fujiwara S, Tatara R, Okazuka K et al.
Key Points:
High expression level of CD25 correlated with poor prognosis following rituximab therapy.
Level of CD25 expression significantly higher in patients with MCL, CLL, MZL, and DLBCL compared to patients with reactive lymphadenopathy.
In CLL patients, the level of CD25 expression wide.
in patients with DLBCL the progression-free survival rate (PFS) after rituximab therapy inferior in patients with CD25+.
Implications:
- Detection of CD 25 expression potential diagnostic and prognostic implications for BCL patients.
View the original abstract on the ASH website.
